Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 446309

Next Previous
Search
Drug Profile

SAR 446309

Alternative Names: AMX-818; HER2-XPAT - Amunix; SAR-446309; VIR-5818

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amunix
  • Class Antineoplastics; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 08 Jan 2025 Efficacy and adverse events data from phase-I/II trial in Solid tumours released by Vir Biotechnology
  • 28 Jul 2022 Amunix initiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Monotherapy) in Australia and Spain
  • 27 Apr 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Australia, Spain (IV) in April 2022(NCT05356741) (Eudra CT 2021-004731-91)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top